Midostaurin
Who holds supplier records for Midostaurin? 8 organisations hold a current record for Midostaurin: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), Italy (1) and Netherlands (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Midostaurin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/midostaurin
Reading the evidence
- 8 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Midostaurin expires 2 Dec 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (8)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Midostaurin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 35231, 34665 · latest filing Sept 2020
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDCompany GMP cert on recordActive DMF 36640 · latest filing Dec 2021
- CONCORD BIOTECH LTDIndia Company GMP cert on recordActive DMF 34976 · latest filing Oct 2020
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 36606 · latest filing Dec 2021
- HUBEI HONCH PHARMACEUTICAL CO LTDCompany GMP cert on recordActive DMF 35562 · latest filing May 2021
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 34522 · latest filing Jan 2020
- PROCOS SPAItaly Company GMP cert on recordActive DMF 35281 · latest filing Nov 2020
- TAPI NL BVNetherlandsActive DMF 35289 · latest filing Nov 2020
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Midostaurin are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- China · Inactive DMF 34990 · filed Dec 2022
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Midostaurin). The latest listed patent expires 2 Dec 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Midostaurin is a multi-targeted kinase inhibitor used in the treatment of acute myeloid leukemia and certain other hematological malignancies. It works by interfering with the action of FLT3 and other kinases involved in cancer cell proliferation.
Chemical identity
- IUPAC name
- N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
- Canonical SMILES
- C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
- InChIKey
- BMGQWWVMWDBQGC-IIFHNQTCSA-N
- Synonyms
- Rydapt API, cgp 41251, cgp-41251, n-benzoylstaurosporine, nsc-656576, nvp-pkc412, pkc 412, pkc-412, rydapt
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Receptor Tyrosine Kinase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Midostaurin?
8 organisations hold an active US FDA Type II Drug Master File or a CEP for Midostaurin: Dr. Reddy's Laboratories Ltd. (India), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, CONCORD BIOTECH LTD (India), Hetero Labs Limited (India), HUBEI HONCH PHARMACEUTICAL CO LTD, MSN Laboratories Private Limited (India), PROCOS SPA (Italy) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Midostaurin Drug Master Files are active?
Dr. Reddy's Laboratories Ltd. (DMF 35231, 34665), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 36640), CONCORD BIOTECH LTD (DMF 34976), Hetero Labs Limited (DMF 36606), HUBEI HONCH PHARMACEUTICAL CO LTD (DMF 35562), MSN Laboratories Private Limited (DMF 34522), PROCOS SPA (DMF 35281) and TAPI NL BV (DMF 35289). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Midostaurin records mean?
1 organisation has only inactive Type II DMFs for Midostaurin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Midostaurin?
Yes. The latest patent listed for an approved US product containing Midostaurin expires 2 Dec 2030, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Midostaurin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Midostaurin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.